床旁GFAP快速识别急性卒中院前脑出血
德国单中心前瞻性诊断准确性研究纳入症状发作6小时内疑似急性卒中患者353例,院前采血、院内用i-STAT-Alinity床旁设备15分钟测血浆GFAP。ICH患者GFAP中位数208 pg/mL,高于IS的30 pg/mL和SM的48 pg/mL(p<0.001);区分ICH与IS/SM的最佳 cutoff 为55 pg/mL,AUC 0.880(95%CI 0.834-0.925,p<0.001)。
要点
- 院前采血、床旁15分钟测GFAP有助于在症状发作6小时内识别ICH。
- 区分ICH与IS/SM的最佳cutoff为55 pg/mL,AUC 0.880。
- 按年龄分组设定cutoff后PPV为90.0%-95.5%,敏感性56.3%-72.4%。
核心结论
- 床旁平台测定院前采集血样的GFAP,可帮助以中至高度PPV识别急性卒中症状患者的ICH。
- 该研究提供Class II证据:症状发作6小时内血浆GFAP升高可准确区分ICH与IS和SM。
研究设计与样本
- 前瞻性诊断准确性研究,在德国巴登-符腾堡州RKH Klinikum Ludwigsburg三级医院开展。
- 纳入症状发作6小时内就诊的急性卒中症状患者353例,平均年龄74.6±13.4岁,女性46.7%。
- 院前阶段采集血样,院内用i-STAT-Alinity设备测血浆GFAP(耗时15分钟),以最终诊断ICH、IS或SM为金标准。
主要发现
- ICH组(n=76)GFAP中位数208 pg/mL(四分位距60-5,907),IS组(n=258)30 pg/mL(29-51),SM组(n=19)48 pg/mL(29-97),p<0.001。
- 区分ICH与IS和SM的最佳GFAP cutoff为55 pg/mL,AUC 0.880(95%CI 0.834-0.925,p<0.001)。
- IS与SM的GFAP水平随年龄增长轻度升高,故按3个年龄组分别确定识别ICH的cutoff。
关键数值与推荐
- 按年龄分组的cutoff:PPV 90.0%-95.5%(最低下限CI 55.0%,最高上限CI 99.3%),敏感性56.3%-72.4%,特异性98.9%-99.0%,NPV 87.5%-92.7%。
- 中度至重度神经功能缺损(NIH Stroke Scale >6)患者中,GFAP <30 pg/mL排除ICH的NPV为100.0%。
临床怎么用
- 在院前采血、院内床旁检测的场景下,GFAP可辅助ICH与IS/SM的鉴别并支持分诊。
- 若经更大独立队列验证并优化入选标准与年龄特异cutoff,GFAP检测可能促进更早启动降压治疗与抗凝逆转。
局限性
- 单中心研究,样本量353例,ICH 76例、SM仅19例。
- 年龄特异cutoff的敏感性仅56.3%-72.4%,部分CI区间较宽。
- 作者指出需在更大独立队列中验证并优化入选标准与年龄特异cutoff。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: The rapid identification of intracerebral hemorrhage (ICH) in patients with symptoms of acute stroke is decisive for prehospital triage and initiation of targeted therapies. Glial fibrillary acidic protein (GFAP) is a highly promising blood-biomarker indicating ICH. In this study, we investigated the potential of a new GFAP test run on a point-of-care platform for distinguishing ICH from ischemic stroke (IS) and stroke mimics (SM) in the prehospital phase. METHODS: This prospective diagnostic accuracy study was conducted at the RKH Klinikum Ludwigsburg, a tertiary care hospital in Baden-Württemberg, Germany. Patients with symptoms of acute stroke admitted within 6 hours of symptom onset were enrolled. Blood samples were collected in the prehospital phase. Plasma GFAP measurements were performed on the i-STAT-Alinity device (duration: 15 minutes) in-hospital. The gold standard was the final diagnosis categorized ICH, IS, or SM. RESULTS: A total of 353 patients were enrolled (mean age 74.6 ± 13.4 years; 46.7% female). GFAP concentrations were elevated in patients with ICH (n = 76; median 208 pg/mL [interquartile range 60-5,907]) compared with IS (n = 258; 30 pg/mL [29-51]) and SM (n = 19; 48 pg/mL [29-97]; p < 0.001). The optimal GFAP cutoff point to differentiate ICH from IS and SM was 55 pg/mL (area under the curve of 0.880, 95% CI 0.834-0.925, p < 0.001). IS and SM GFAP levels slightly increased in parallel with increasing age. Hence, different GFAP cutoff points were determined to identify ICH across 3 age groups with moderate to high positive predictive values (PPVs) (90.0%-95.5%; minimum lower CI 55.0%, maximum upper CI 99.3%) (sensitivity values 56.3%-72.4%, specificity values 98.9%-99.0% and negative predictive values [NPVs] 87.5%-92.7%). Vice versa, in patients with a moderate to severe neurologic deficit (NIH Stroke Scale >6), GFAP values <30 pg/mL ruled out ICH with a NPV of 100.0%. DISCUSSION: Laboratory GFAP measurements on a point-of-care platform in blood samples collected from patients with symptoms of acute stroke in the prehospital phase can help to identify ICH with moderate to high PPV. Following confirmation in larger independent cohorts using optimized eligibility criteria and validated age-specific cutoff values, GFAP testing could facilitate optimized triage and the initiation of blood pressure-lowering therapy and anticoagulation reversal in earlier time frames. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that elevated plasma GFAP levels within 6 hours of symptom onset accurately distinguish patients with ICH from IS and SM.
引用
- Kalra LP, Zylyftari S, Blums K, et al. Rapid Diagnosis of Intracerebral Hemorrhage in Patients With Acute Stroke by Measuring Prehospital GFAP Levels on a Point-of-Care Device (DETECT). Neurology. 2025. PMID: 40570271. doi:10.1212/WNL.0000000000213823
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。